The past year or so has shown that Novo Nordisk (NYSE:NVO) isn't immune from seeing some serious challenges to its business. Between a serious setback in its insulin development program and nagging worries about incretins, 2013 isn't going to go down as a great year in the history of Novo Noridsk. All of that said, I have little doubt that the company will continue to be an uncommonly strong pharma company, with huge leverage to one of the fastest-growing diseases in the world. Although I think broadening both the diabetes business and the overall business would be beneficial, Novo Nordisk really doesn't have to do much to continue performing at a high level. Q2 Earnings – Not All They're Cracked Up To BeAlthough it seems like a fair number of sell-side analysts have gotten themselves excited about Novo Nordisk's second quarter results, I don't think they're all that strong on balance. Revenue did grow 10% from last year, and that was good for a 2% beat relative to expectations. The problem, though, is that growth would have been more on the order of 8% were it not for some rebate reversals and the timing of tenders. That would have still made for a good quarter, but I think investors should note that pretty much all of the upside this quarter was driven by those factors and the underlying business was more or less in line. SEE: Earnings: Quality Means Everything Gross margin improved about 70bp as reported, and operating income rose 12%, or almost 7% more than expected. Again, though, those rebate reversals went straight through to profits, so this isn't evidence of strong underlying profit improvements. The Diabetes Franchise Continue To Grow Like A ChampDiabetes revenue rose 11% this quarter, and the growth would have still been impressive after netting out the aforementioned benefits. The company's analog insulin business continues to grow at a double-digit clip (up 12%), while Victoza grew 26% and seems to be losing no momentum to Bristol-Myers (NYSE:BMY)/AstraZeneca's (NYSE:AZN) Bydureon. Better still, the threats to this business seem to be slowly fading away. Biosimilar analog insulin has proven a great deal more challenging than previously thought, with Teva (Nasdaq:TEVA) and Lonza recently dissolving their four-year partnership to develop such a product. Add that to similar past decisions from Actavis (NYSE:ACT) and Pfizer (NYSE:PFE), and biosimilar insulin is looking less and les of a clear and present danger to Novo Nordisk (as well as its rivals Sanofi (NYSE:SNY) and Lilly (NYSE:LLY). That should give the company more breathing room as well. Management has announced that it intends to begin a 7,500-patient CV outcomes study on Tresiba later this year, which would conceivably have the company re-filing for FDA approval before the end of 2016. That is not great news, particularly with the data on Sanofi's new U300 insulin at the recent ADA meeting, but it would look a lot worse if biosimilar Levemir and NovoRapid were close at hand. I still do wonder, though, if Novo Nordisk shouldn't broaden its horizons a bit. The insulin business is a cash-generating fortress and Victoza is still growing well, but there are persistent safety concerns about incretins like Victoza and perhaps the company would do well to add an SGLT-1/2 compound to its portfolio and/or expand its earlier-stage research on non-insulin diabetes treatments.SEE: Evaluating Pharmaceutical Companies Will Victoza Gain Any Traction In Obesity?Although Novo Nordisk did announce that an oral GLP-1 drug is moving into Phase II testing, there aren't likely to be a lot of near-term positive news events other than a launch of Victoza as an obesity treatment. Some will scoff at the idea that a drug that has to be injected daily could get any traction in the market, but I think the needle isn't the problem. Given the efficacy that Victoza has shown, I believe people would use it. The problem is the price – at $20 a day, I'm not sure the benefits are compelling enough for the drug to get wide acceptance, though some analysts are still projecting $1 billion or more in sales from this indication. The Bottom LineComplaining about Novo Nordisk's valuation is like complaining about the heat in summertime – it may be true, but it's not going to change anything. Low teens free cash flow growth is good for a fair value around $160, but Wall Street has long showed that it is willing to assign a lower discount rate to Novo Nordisk's cash flow than I deem attractive. Given the underlying growth, Novo Nordisk isn't a bad pick in an expensive sector, but investors should understand that Wall Street's positive bias toward the company will mean that any disappointments or bad news will be punished harshly. Disclosure – At the time of writing, the author did not own shares of any company mentioned in this article.

Related Articles
  1. Stock Analysis

    The Biggest Risks of Investing in Pfizer Stock

    Learn the biggest potential risks that may affect the price of Pfizer's stock, complete with a fundamental analysis and review of other external factors.
  2. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  3. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  4. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  5. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  6. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  7. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  8. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  9. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  10. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center